Medplus Health Services
832.35
+18.55(+2.28%)
Market Cap₹9,962.72 Cr
PE Ratio54.62
IndustryRetail
Company Performance:
1D+2.28%
1M-7.56%
6M+12.52%
1Y+29.62%
5Y-25.76%
View Company Insightsright
Latest news about Medplus Health Services
MedPlus Subsidiary Faces Four-Day Drug License Suspension in Telangana 2 days ago
Medplus Health Services Limited's subsidiary, Optival Health Solutions, received a four-day suspension order for its drug license at a store in Quthubullapur, Telangana. The suspension, citing violations under the Drugs and Cosmetics Act, is expected to result in a potential revenue loss of approximately Rs. 0.80 lakhs. The company promptly reported this development to stock exchanges in compliance with SEBI regulations.
MedPlus Health Services Reports Q1 Results: Revenue Growth Amid Expansion and Private Label Push Aug 07, 2025
MedPlus Subsidiary Faces Drug License Suspensions Across Three States Aug 06, 2025
MedPlus Health Services Reports 195% Surge in Q1 Profit, Approves Key Appointments Aug 02, 2025
MedPlus Subsidiary Faces Two-Day Drug License Suspension in Karnataka Aug 02, 2025
More news about Medplus Health Services
31Jul 25
MedPlus Subsidiary Faces Drug License Suspensions at Two Telangana Stores
Optival Health Solutions, a subsidiary of MedPlus Health Services Limited, has received suspension orders for drug licenses at two stores in Telangana. The suspensions, issued by the Assistant Director of Drugs Control Administration in Warangal, affect a store in Station Ghanpur for five days and another in Jangaon, Warangal for three days. The estimated revenue loss is 0.98 lakhs for the Station Ghanpur store and 0.40 lakhs for the Jangaon store. MedPlus has notified the BSE and NSE about this development in compliance with SEBI regulations.
31Jul 25
MedPlus Subsidiary Faces Drug License Suspensions at Two Telangana Stores
Optival Health Solutions, a subsidiary of MedPlus Health Services, received suspension orders for drug licenses at two stores in Telangana. The Station Ghanpur store faces a five-day suspension, while the Jangaon store faces a three-day suspension. The estimated revenue loss is Rs. 0.98 lacs and Rs. 0.40 lacs respectively. The suspensions were issued for violations under the Drugs and Cosmetics Act and Rules. MedPlus promptly disclosed this information in compliance with SEBI regulations.
29Jul 25
MedPlus Subsidiary Faces One-Day Drug License Suspension in Karnataka
Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, received a one-day suspension order for its drug license at a store in Gadag, Karnataka. The order was issued by the Assistant Director of Drugs Control Administration under the Drugs and Cosmetics Act. The company estimates a potential revenue loss of Rs. 0.21 lacs due to this suspension. Medplus Health Services has disclosed this information to stock exchanges in compliance with SEBI regulations.
26Jul 25
MedPlus Subsidiary Faces 3-Day Drug License Suspension in Visakhapatnam
Optival Health Solutions, a subsidiary of Medplus Health Services, received a three-day drug license suspension order for a store in Visakhapatnam, Andhra Pradesh. The suspension, citing violations under the Drugs and Cosmetics Act, is expected to result in a potential revenue loss of Rs. 0.69 lakhs. The company disclosed this information in compliance with SEBI regulations.
23Jul 25
MedPlus Subsidiary Faces 3-Day Drug License Suspension in Tamil Nadu
Optival Health Solutions, a subsidiary of Medplus Health Services, received a three-day suspension order for a drug license at its store in MGR Nagar, Tamil Nadu. The suspension, issued on July 22, 2025, cites violations under the Drugs and Cosmetics Act, 1940 and Rules, 1945. The company estimates a potential revenue loss of Rs. 3.03 lakhs due to this temporary suspension. Medplus Health Services disclosed this incident in compliance with SEBI regulations.
15Jul 25
MedPlus Health Services Subsidiary Faces Drug License Suspensions in Karnataka and Telangana
Optival Health Solutions, a subsidiary of MedPlus Health Services, received suspension orders for drug licenses at five retail pharmacy outlets in Karnataka and Telangana. The suspensions, lasting 2 to 7 days, were issued between July 10-14, 2025, under the Drugs and Cosmetics Act. The company estimates potential revenue losses of approximately ₹4.78 lakh across the affected stores. The suspensions were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. MedPlus has disclosed this information in compliance with SEBI regulations.
27May 25
MedPlus Health Services Reports 53.6% Surge in Q4 Net Profit
MedPlus Health Services announced impressive Q4 results with net profit soaring 53.6% year-over-year to ₹51.30 crore, despite a modest 1.3% revenue increase to ₹1,510.00 crore. The company demonstrated significant improvements in operational efficiency, with EBITDA rising 42.7% to ₹145.00 crore and operating profit margin expanding to 8.49% from 6.37% in the previous year. These results highlight MedPlus's effective cost management and operational strategies in the competitive Indian pharmacy retail sector.
Medplus Health Services
832.35
+18.55
(+2.28%)
1 Year Returns:+29.62%
Industry Peers
Trimurthi
41.29
(+3.98%)